Cargando…
Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging
BACKGROUND: Antiangiogenic treatments have been shown to increase blood perfusion and oxygenation in some experimental tumors, and to reduce blood perfusion and induce hypoxia in others. The purpose of this preclinical study was to investigate the potential of dynamic contrast enhanced magnetic reso...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647606/ https://www.ncbi.nlm.nih.gov/pubmed/26573613 http://dx.doi.org/10.1186/s12885-015-1918-1 |
_version_ | 1782401136192389120 |
---|---|
author | Gaustad, Jon-Vidar Simonsen, Trude G. Smistad, Ragnhild Wegner, Catherine S. Andersen, Lise Mari K. Rofstad, Einar K. |
author_facet | Gaustad, Jon-Vidar Simonsen, Trude G. Smistad, Ragnhild Wegner, Catherine S. Andersen, Lise Mari K. Rofstad, Einar K. |
author_sort | Gaustad, Jon-Vidar |
collection | PubMed |
description | BACKGROUND: Antiangiogenic treatments have been shown to increase blood perfusion and oxygenation in some experimental tumors, and to reduce blood perfusion and induce hypoxia in others. The purpose of this preclinical study was to investigate the potential of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) and diffusion weighted MRI (DW-MRI) in assessing early effects of low dose bevacizumab treatment, and to investigate intratumor heterogeneity in this effect. METHODS: A-07 and R-18 human melanoma xenografts, showing high and low expression of VEGF-A, respectively, were used as tumor models. Untreated and bevacizumab-treated tumors were subjected to DCE-MRI and DW-MRI before treatment, and twice during a 7-days treatment period. Tumor images of K(trans) (the volume transfer constant of Gd-DOTA) and v(e) (the fractional distribution volume of Gd-DOTA) were produced by pharmacokinetic analysis of the DCE-MRI data, and tumor images of ADC (the apparent diffusion coefficient) were produced from DW-MRI data. RESULTS: Untreated A-07 tumors showed higher K(trans), v(e), and ADC values than untreated R-18 tumors. Untreated tumors showed radial heterogeneity in K(trans), i.e., K(trans) was low in central tumor regions and increased gradually towards the tumor periphery. After the treatment, bevacizumab-treated A-07 tumors showed lower K(trans) values than untreated A-07 tumors. Peripherial tumor regions showed substantial reductions in K(trans), whereas little or no effect was seen in central regions. Consequently, the treatment altered the radial heterogeneity in K(trans). In R-18 tumors, significant changes in K(trans) were not observed. Treatment induced changes in tumor size, v(e), and ADC were not seen in any of the tumor lines. CONCLUSIONS: Early effects of low dose bevacizumab treatment may be highly heterogeneous within tumors and can be detected with DCE-MRI. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1918-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4647606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46476062015-11-18 Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging Gaustad, Jon-Vidar Simonsen, Trude G. Smistad, Ragnhild Wegner, Catherine S. Andersen, Lise Mari K. Rofstad, Einar K. BMC Cancer Research Article BACKGROUND: Antiangiogenic treatments have been shown to increase blood perfusion and oxygenation in some experimental tumors, and to reduce blood perfusion and induce hypoxia in others. The purpose of this preclinical study was to investigate the potential of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) and diffusion weighted MRI (DW-MRI) in assessing early effects of low dose bevacizumab treatment, and to investigate intratumor heterogeneity in this effect. METHODS: A-07 and R-18 human melanoma xenografts, showing high and low expression of VEGF-A, respectively, were used as tumor models. Untreated and bevacizumab-treated tumors were subjected to DCE-MRI and DW-MRI before treatment, and twice during a 7-days treatment period. Tumor images of K(trans) (the volume transfer constant of Gd-DOTA) and v(e) (the fractional distribution volume of Gd-DOTA) were produced by pharmacokinetic analysis of the DCE-MRI data, and tumor images of ADC (the apparent diffusion coefficient) were produced from DW-MRI data. RESULTS: Untreated A-07 tumors showed higher K(trans), v(e), and ADC values than untreated R-18 tumors. Untreated tumors showed radial heterogeneity in K(trans), i.e., K(trans) was low in central tumor regions and increased gradually towards the tumor periphery. After the treatment, bevacizumab-treated A-07 tumors showed lower K(trans) values than untreated A-07 tumors. Peripherial tumor regions showed substantial reductions in K(trans), whereas little or no effect was seen in central regions. Consequently, the treatment altered the radial heterogeneity in K(trans). In R-18 tumors, significant changes in K(trans) were not observed. Treatment induced changes in tumor size, v(e), and ADC were not seen in any of the tumor lines. CONCLUSIONS: Early effects of low dose bevacizumab treatment may be highly heterogeneous within tumors and can be detected with DCE-MRI. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1918-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-14 /pmc/articles/PMC4647606/ /pubmed/26573613 http://dx.doi.org/10.1186/s12885-015-1918-1 Text en © Gaustad et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Gaustad, Jon-Vidar Simonsen, Trude G. Smistad, Ragnhild Wegner, Catherine S. Andersen, Lise Mari K. Rofstad, Einar K. Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging |
title | Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging |
title_full | Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging |
title_fullStr | Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging |
title_full_unstemmed | Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging |
title_short | Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging |
title_sort | early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647606/ https://www.ncbi.nlm.nih.gov/pubmed/26573613 http://dx.doi.org/10.1186/s12885-015-1918-1 |
work_keys_str_mv | AT gaustadjonvidar earlyeffectsoflowdosebevacizumabtreatmentassessedbymagneticresonanceimaging AT simonsentrudeg earlyeffectsoflowdosebevacizumabtreatmentassessedbymagneticresonanceimaging AT smistadragnhild earlyeffectsoflowdosebevacizumabtreatmentassessedbymagneticresonanceimaging AT wegnercatherines earlyeffectsoflowdosebevacizumabtreatmentassessedbymagneticresonanceimaging AT andersenlisemarik earlyeffectsoflowdosebevacizumabtreatmentassessedbymagneticresonanceimaging AT rofstadeinark earlyeffectsoflowdosebevacizumabtreatmentassessedbymagneticresonanceimaging |